Atrium Therapeutics, Inc. 8K

Atrium Therapeutics reported Q2 2026 financial results, announced IND clearance and trial initiation activities for ATR 1072 in PRKAG2 syndrome, and disclosed a $15 million milestone earned under its Bristol Myers Squibb collaboration, extending its cash runway to mid-2028.

Atrium Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighting FDA clearance of its IND application for ATR 1072 and a Health Canada No Objection Letter enabling the launch of Corventis, a Phase 1/2 clinical trial in PRKAG2 syndrome, initiation of clinical site activities with first patient enrollment expected by year-end 2026, and achievement of a second collaboration milestone under its global cardiovascular agreement with Bristol Myers Squibb that will trigger a $15 million payment in the third quarter. The company reported $3.0 million of collaboration revenue in the quarter, primarily from R&D services for BMS, research and development expenses of $15.3 million, general and administrative expenses of $10.3 million, and ended the quarter with $263.9 million in cash, cash equivalents and short-term investments, which it believes will fund operations through mid-2028 including the anticipated milestone receipt. Atrium also outlined pipeline expectations, including initial Corventis proof-of-concept data in the second half of 2027, IND-enabling work for ATR 1086 beginning in 2026 with an IND filing planned in 2027, and advancement of two additional undisclosed rare cardiomyopathy programs.

Filing Facts

CIK

2093101

Ticker

RNA

Form

8K

Source Type

fda

Accession

0001193125-26-349482

Alert Tier

7